Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • RINVOQ
      RINVOQ
      Humira
      Humira
      Prescribing Guide
      Prescribing Guide
      Previous
      Next

      Education and services for you

      TDM

      We know therapeutic drug monitoring (TDM) is a vital resource for your clinical toolkit. AbbVie has partnered with SONIC pathology to increase access to this service for eligible patients.

      LEARN MORE ➜

      Click to view

      Unveiling the future of Rinvoq in CD. Learn about the new reimbursement information of Rinvoq in CD.

      LEARN MORE ➜

      humira tile
      Rinvoq tile
      Rinvoq tile
      Contact a rep
      Contact a rep

      Your decisions have transformed the
      lives of many patients

      AbbVie and HUMIRA - your partners on the journey.*

      *AbbVie medications and programs are designed to support patients on their health journey.

      Your decisions have transformed the lives of many patients

      AbbVie and HUMIRA - your partners on the journey.*

      *AbbVie medications and programs are designed to support patients on their health journey.

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      HUMIRA: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis or paediatric psoriasis.

      Please review the full Product Information (PI) before prescribing, available below.

      HUMIRA PI

      RINVOQ PI

      References: 1. Burmester GR et al. Ann Rheum Dis 2009;68(12):1863–9. 2. AbbVie Data on File. CLA-AU-210006. 3. Nash P et al. Rheumatol Ther 2016;3(2):257–70. 4. Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Adalimumab Pharmaceutical Benefits Scheme changes - 1 April 2021. Accessed: July 2022. 5. HUMIRA Product Information.

      AU-HUMG-200014. November 2024